HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Neutral 56.9%

Neg 0% Neu 56.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.